血管生成抑制因子的研究进展  

Research Advancement of Endogenous Angiogenesis Inhibitors

作　　者：吴江雪[1] 徐本玲[1] 黄文林[1] 

机构地区：[1]中山大学肿瘤防治中心实验研究部,广东广州510060

出　　处：《癌症》2005年第3期376-384,共9页Chinese Journal of Cancer

基　　金："863"计划滚动资金项目(No.2003AA216061)~~

摘　　要：血管生成与肿瘤的生长、侵袭和转移密切相关,目前,以抑制血管生成为靶点治疗肿瘤有望成为抗肿瘤新疗法之一。近年来,研究发现了多种内源性血管生成抑制因子,其中一些已进入了临床试验阶段。本文对内源性血管生成抑制因子的结构、功能、作用机制及其在肿瘤治疗中的应用进行综述。Angiogenesis is required for invasive tumor growth and metastasis. Inhibition of angiogenesis is considered to be a promising approach of antitumor therapy. Recently, many endogenous angiogenesis inhibitors have been discovered, some of them are currently in various stages of clinical trials. This review focused on the structure, function, and mechanism of endogenous angiogenesis inhibitors, and their potential in treating tumor.

关 键 词：肿瘤 血管生成抑制因子 血管生成抑制素 内皮细胞抑制素 

分 类 号：R730.2[医药卫生—肿瘤] R730.5[医药卫生—临床医学]